Includes 15.6 Metres Averaging 1.47% Cu and 8.5 g/t Ag E Zone Skarn Returns 29.7 Metres Averaging 1.92% Cu and 15.2 g/t Ag Infill Drilling Continues to Extend Deposit at Depth Below 2024 MRE MONTREAL, June 12, 2025 (GLOBE NEWSWIRE) -- Osisko Metals Incorporated (the “Company or "Osisko Metals") (TSX-V: OM; OTCQX: OMZNF; FRANKFURT: 0B51) is pleased to announce new drilling results from the 2025 drilling program at the Gaspé Copper Project, located in the Gaspé Peninsula of Eastern Québec. Results for eight ...

Outset Medical (OM) FY 2025 Conference June 11, 2025 11:20 AM ET Speaker0 Anyway, I guess that's a good segue here. Just to remind everyone that these events are not these meetings are not open to the press. So with that, we'll get we'll get started here with last session of the morning here with very pleased to welcome the management team from outset medical Leslie Triggs, Chief Executive Officer and Renee Gaeta, who is recently appointed very recently appointed as CFO. So congratulations on the role and l ...

Company Overview - Outset Medical, Inc. is a medical technology company focused on pioneering technology to reduce the cost and complexity of dialysis [3] - The Tablo® Hemodialysis System is FDA cleared for use from the hospital to the home, representing a significant technological advancement in dialysis [3] - Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by anyone [3] Product Features - The integration of water purification and on-demand dialysate production enables Tablo to function as a "dialysis clinic on wheels" [3] - Tablo features 2-way wireless data transmission and a proprietary data analytics platform, promoting a holistic approach to dialysis care [3] Upcoming Events - Management will present at the Goldman Sachs 46th Annual Healthcare Conference on June 11, 2025, at 11:20 a.m. Eastern time [1] - A live and archived webcast of the presentation will be available on the "Investors" section of the Outset website [2]

Core Viewpoint - Outset Medical, Inc. has appointed Renee Gaeta as the new Chief Financial Officer, effective immediately, as the company aims to drive growth and achieve near-term profitability [1][2]. Company Overview - Outset Medical is a medical technology company focused on reducing the cost and complexity of dialysis through its innovative Tablo® Hemodialysis System, which is FDA cleared for use in various settings [4]. - The Tablo system integrates water purification and on-demand dialysate production, allowing for flexible dialysis delivery and operational simplification for providers [4]. Leadership Appointment - Renee Gaeta brings extensive financial and leadership experience from her previous roles as CFO at Shockwave Medical and Eko Health, among others [2][3]. - Gaeta's appointment is seen as a strategic move to support Outset's next phase of growth and profitability goals [2]. Financial Guidance - Outset has reiterated its financial guidance for 2025, projecting revenues between $115 million and $125 million, with a non-GAAP gross margin expected to be in the high-30% range [2].

Financial Data and Key Metrics Changes - The preliminary results indicated that the proposal to approve the 2024 compensation of named executive officers was approved, reflecting shareholder support for executive pay practices [13] - The amendment to the 2020 equity incentive plan to increase the number of shares available by 1,950,000 shares was also approved, indicating a positive outlook on employee incentives [13] - The ratification of KPMG LLP as the independent registered public accounting firm for 2025 was passed, ensuring continuity in financial oversight [13] Business Line Data and Key Metrics Changes - No specific data or metrics regarding individual business lines were discussed during the meeting [15] Market Data and Key Metrics Changes - No specific market data or metrics were provided in the meeting [15] Company Strategy and Development Direction - The company is focused on enhancing its equity incentive plan and employee stock purchase plan, which suggests a strategy aimed at retaining talent and aligning employee interests with shareholder value [13] Management Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting [15] Other Important Information - The meeting was attended by key executives and board members, including the CEO and CFO, indicating strong leadership presence [3][2] - The meeting was recorded, and a webcast playback will be available for one year, ensuring transparency for shareholders [6] Q&A Session Summary Question: Were there any questions regarding the company's business? - There were no questions submitted during the Q&A session [15]

Core Points - Osisko Metals Incorporated held its annual and special meeting of shareholders, with 290,548,699 common shares represented, accounting for approximately 47.67% of total issued shares [2] - All matters presented for shareholder approval were overwhelmingly approved, including the adoption of the Omnibus Plan, which reserves a maximum of 60,956,063 common shares for issuance [2][6] - The company is focused on resource expansion at the Gaspé Copper mine, which has indicated mineral resources of 824 million tonnes grading 0.34% CuEq and inferred resources of 670 million tonnes grading 0.38% CuEq [4] - The Pine Point project, a joint venture with Appian Capital Advisory LLP, has indicated mineral resources of 49.5 million tonnes at 5.52% ZnEq and inferred resources of 8.3 million tonnes at 5.64% ZnEq [5][7] Company Overview - Osisko Metals is a Canadian exploration and development company focused on critical metals, particularly copper and zinc [4] - The company acquired a 100% interest in the Gaspé Copper mine from Glencore Canada Corporation in July 2023, which is strategically located near existing infrastructure in Québec [4] - The Pine Point project is one of Canada's largest past-producing zinc mining camps, located in the Northwest Territories with good access to infrastructure [5][7]

Outset Medical (OM) Q1 2025 Conference Call Summary Company Overview - **Company**: Outset Medical (OM) - **Industry**: Medical Devices, specifically focused on dialysis solutions Key Points and Arguments Financial Performance - **Q1 Revenue**: Achieved a 7% upside surprise on revenue, marking the first year-over-year increase in five quarters [3] - **Console Growth**: Console revenue grew approximately 23% sequentially, the first increase in six quarters [3] - **Recurring Revenue**: Strong double-digit growth in recurring revenues, which include consumables and service offerings [4] - **Gross Margin**: Reported gross margin of 37.6%, with expectations to exit the year at around 40% [4][46] Commercial Transformation - **Sales Transformation**: A comprehensive commercial transformation initiated about 18 months ago is showing positive results, with Q1 serving as a proof point [5][38] - **Sales Process Improvements**: New sales processes and leadership have improved the sales pipeline and closing rates [14][15] Market Demand and Value Proposition - **Demand for Tableau**: Strong demand exists for Tableau, which saves hospitals money by allowing them to insource dialysis services [7][8] - **Cost Savings**: Hospitals can see payback on Tableau investments within a year, with significant cost savings compared to outsourcing [22][24] Pipeline and Growth Metrics - **Pipeline Health**: The company is pleased with the composition and growth of its sales pipeline, which has seen growth in both Q4 and Q1 [12] - **Installed Base**: The current installed base is expected to generate approximately $500 million in recurring revenues over the coming years [30] Operational Insights - **Field Service Team**: Investments are being made in the field service engineering team to enhance customer satisfaction, which currently stands at over 90% [35] - **Remote Diagnostics**: Investments in remote repair and diagnostics are expected to improve service efficiency [36] Guidance and Future Outlook - **Conservative Guidance**: Despite a strong Q1, the company has chosen not to raise its guidance, opting for a conservative approach [39][41] - **Long-term Goals**: Aiming for adjusted EBITDA positivity at less than $200 million in sales, with a focus on achieving 50% gross margins [52][53] Market Penetration - **Acute Market Penetration**: Currently about 10% penetrated in the acute market, with significant room for growth [67] - **Home Market**: Only 1,500 consoles sold into the home market against a potential 600,000 chronic patients, indicating early-stage market penetration [68] Strategic Focus - **US Market Focus**: The company is primarily focused on the US market, which has a total addressable market (TAM) of $11 billion [62] - **Potential Partnerships**: While open to partnerships, the current strategy emphasizes capitalizing on existing market opportunities [64] Additional Important Insights - **Clinical Benefits**: Insourcing with Tableau has led to significant clinical improvements, including a 75% reduction in infection rates in some hospitals [25] - **Customer Engagement**: A large reference account list is available to assist prospects in decision-making [26] This summary encapsulates the key insights from the Outset Medical Q1 2025 conference call, highlighting the company's financial performance, market strategies, and future outlook.

Company Overview - Outset Medical, Inc. is a medical technology company focused on pioneering technology to reduce the cost and complexity of dialysis [4] - The company's flagship product, the Tablo® Hemodialysis System, is FDA cleared for use from hospital to home, representing a significant advancement in dialysis technology [4] - Tablo integrates water purification and on-demand dialysate production, allowing it to function as a mobile dialysis clinic with 2-way wireless data transmission and a proprietary data analytics platform [4] Leadership Changes - Kevin O'Boyle has been appointed to the Board of Directors and as chair of the Audit Committee, bringing over 20 years of healthcare leadership experience [2][3] - O'Boyle's previous roles include CFO of several publicly traded companies and board director of six public medical device companies, which will aid Outset in its growth [2] - Dale E. Jones has stepped down from the Board, with appreciation expressed for his contributions during a critical period for the company [3]

Company Overview - Outset Medical, Inc. is a medical technology company focused on pioneering technology to reduce the cost and complexity of dialysis [3] - The Tablo® Hemodialysis System is FDA cleared for use from the hospital to the home, representing a significant technological advancement in dialysis [3] - Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by anyone [3] Technological Innovation - The integration of water purification and on-demand dialysate production enables Tablo to function as a "dialysis clinic on wheels" [3] - Tablo features 2-way wireless data transmission and a proprietary data analytics platform, promoting a holistic approach to dialysis care [3] Upcoming Events - Members of Outset's management will participate in the RBC Capital Markets Global Health Care conference on May 20, 2025, at 10:30 a.m. Eastern time [1] - A live and archived webcast of the session will be available on the "Investors" section of the Outset website [2]

Company Performance - Outset Medical, Inc. reported a quarterly loss of $3.24 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.97, representing an earnings surprise of -234.02% [1] - The company posted revenues of $29.75 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 7.49%, and showing an increase from $28.17 million in the same quarter last year [2] - Over the last four quarters, Outset Medical has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Outset Medical shares have declined approximately 30.7% since the beginning of the year, in contrast to the S&P 500's decline of -4.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.95 on revenues of $29.5 million, and for the current fiscal year, it is -$3.92 on revenues of $120.09 million [7] Industry Outlook - The Medical Info Systems industry, to which Outset Medical belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5][6]